What happens when the insurance company's first line of response is to deny, deny, deny? How does this increase in oversight from third-party payors impact the process of rare pituitary disease medicine authorizations indicated for treatment? Why do insurance companies use these delay tactics? What role do treatment guidelines play? What can we do? In this podcast, PWN cofounder Dr. Lewis Blevins shares his experiences and frustration with these problematic issues.
My conversation with Risa Heidt, who will be riding her bike from Canada to Mexico to promote awareness of rare pituitary diseases: Marisa "Risa" Heidt, diagnosed with acromegaly (a rare disease of the pituitary gland), in 2018, is undertaking this 1845-mile challenge starting this September 11. Click here for more details and what you can do to help.
In today's podcast, we welcome Claire Murphy, Director of the Orphan Drug Congress, to talk about this important, innovative event. The Congress brings together leading industry, government and regulatory authorities, patient advocacy groups, payers, investors, and solution providers, advancing orphan drug development and improving access to life-saving therapies.